The NAD+ Longevity Stack: What the Protocols Actually Look Like in Practice

You've read the David Sinclair interviews, you've seen the nicotinamide riboside capsule bottles stacking up in longevity influencer content, and now you're staring at a supplement shelf with $60 NR and $90 NMN bottles side by side, wondering whether either of them will do anything measurable — or whether the IV NAD+ clinic down the street at $350 a drip is the smarter spend. Most research rabbit holes end here: not in clarity, but in a thicker fog of competing claims and no pricing anchor.

Here's what the current evidence, pricing landscape, and clinical practice actually look like.

---

What NAD+ Protocols Are Trying to Do

NAD+ (nicotinamide adenine dinucleotide) sits at the centre of cellular energy metabolism and is a required substrate for sirtuin enzymes, which regulate DNA repair and stress response pathways. NAD+ levels in human tissue decline substantially with age — studies using HPLC-mass spectrometry have measured whole-blood NAD+ concentrations around 20–30 µmol/L in adults over 60, compared to 40–60 µmol/L in adults in their 30s.

The protocols designed to address this fall into three tiers: oral precursor supplementation (NR or NMN), subcutaneous or intramuscular injections of NAD+ precursors, and intravenous NAD+ infusions. Each tier makes meaningfully different claims, carries different costs, and has meaningfully different evidence behind it.

---

The Oral Supplement Tier: What the Data Actually Shows

The most-cited human trials on oral NR (nicotinamide riboside) are the Elysium BASIS studies and the Trammell et al. 2016 paper (Cell Metabolism, n=12), which showed that 1,000 mg/day of NR raised whole-blood NAD+ by approximately 60% over baseline after four weeks in healthy adults. That's a real, reproducible signal. The problem is the gap between "raised NAD+ in blood" and "demonstrated clinical outcome."

The Martens et al. 2018 trial (Nature Communications, n=24 older adults, 1,000 mg/day NR for six weeks) found increased skeletal muscle NAD+ metabolites but no significant improvement in metabolic function, blood pressure, or cardiovascular markers compared to placebo. The precursor works as a precursor. Whether elevated NAD+ translates to the longevity outcomes being marketed is still an open question.

Current oral NMN pricing in mid-2026 runs roughly $60–$120 for a 30-day supply at the 500 mg/day doses used in trials. NR tends to be $50–$90 for equivalent dosing. Reputable brands — Elysium, Tru Niagen, Renue By Science — all sit at the higher end of those ranges.

---

The IV Tier: Fast, Costly, and Mostly Uncharted

Intravenous NAD+ infusions typically deliver 250–1,000 mg per session administered over two to four hours. At most US longevity clinics in 2026, a single 500 mg infusion runs $350–$600. A common starter protocol of four sessions over two weeks therefore costs $1,400–$2,400 before any follow-up maintenance.

The anecdotal case for IV NAD+ is real — subjective energy, mood lift, and reduced brain fog are commonly reported, and there's a plausible mechanism: bypassing gut absorption and hepatic first-pass metabolism. The clinical trial data is thin. The FDA has not approved IV NAD+ for any indication, and published data is largely confined to addiction medicine contexts — small studies in alcohol and opioid withdrawal — not healthy aging populations. If you're looking at longevity clinics in Los Angeles pricing IV drips as a cornerstone anti-aging protocol, you're paying for anecdotal outcomes with a plausible mechanism, not evidence-based medicine. That's a legitimate choice, but it should be a clear-eyed one.

---

Where Telehealth Longevity Platforms Fit In

The more useful mid-ground in 2026 is the structured telehealth longevity program that layers NAD+ precursors into a broader protocol alongside peptides, hormonal optimisation, and biomarker tracking. Platforms like Yucca Health and System Labs have built membership models that combine physician oversight with quarterly labs, allowing NAD+ status to be tracked alongside metabolic and inflammatory markers rather than treated as an isolated supplement decision.

This matters because NAD+ doesn't operate in isolation. The sirtuin activation that NAD+ enables interacts directly with mTOR signalling, insulin sensitivity, and mitochondrial biogenesis — all of which are addressable through the same protocol stack. Evaluating NAD+ boosters without tracking those downstream markers is like titrating a medication without monitoring the outcome.

The broader online longevity programs space has standardised around a lab panel that typically includes plasma NAD+ metabolites, hs-CRP, fasting insulin, and an IGF-1 baseline — giving practitioners an actual starting point rather than a subjective impression.

---

Stack Design: What Practitioners Are Actually Combining

The most common clinical stack in 2026 combines an oral NMN or NR base (500 mg/day), a pterostilbene or resveratrol co-factor (100–200 mg/day) on the theory that sirtuin activation requires both NAD+ and a SIRT1 activator, and periodic IV top-ups — one session monthly rather than weekly loading. Some protocols add BPC-157 for gut barrier support on the premise that intestinal integrity affects NMN absorption, though the evidence chain there is longer.

What practitioners are moving away from: mega-dosing NMN above 1,000 mg/day without labs to justify it — NAD+ is a methyl group consumer, and there are theoretical concerns about methylation depletion at high doses — and treating IV NAD+ as a substitute for foundational metabolic work.

---

The Actual Takeaway

Starting from scratch, oral NMN or NR at 500 mg/day is the lowest-risk, evidence-backed entry point. Build a baseline lab panel — plasma NAD+ metabolites, hs-CRP, fasting insulin, IGF-1 — before adding anything else. IV protocols make more sense as quarterly top-ups inside a tracked program than as standalone sessions at $500 a drip. If you're going to spend serious money, spend it inside a structure that measures outcomes — the longevity clinics directory lets you filter by protocol type and physician oversight model.

The data trail is real but incomplete. Spending ahead of the evidence is a personal call — make sure it's an informed one.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---